PMID- 19795170
OWN - NLM
STAT- MEDLINE
DCOM- 20100324
LR  - 20211020
IS  - 1432-1750 (Electronic)
IS  - 0341-2040 (Linking)
VI  - 187
IP  - 6
DP  - 2009 Nov-Dec
TI  - Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell 
      lung carcinomas and their relationship with immune cell infiltration.
PG  - 401-11
LID - 10.1007/s00408-009-9181-3 [doi]
AB  - Cancer-testis antigens (CTAs) are expressed only in many cancers and limited 
      immunoprivileged sites such as the testis and placenta. Dendritic cells (DCs) and 
      CD8+ T lymphocytes (CTLs) play roles in the immune responses to tumor growth and 
      may affect the prognosis of cancers. This study was designed to investigate the 
      clinicopathologic significance of CTA expression in non-small-cell lung 
      carcinomas (NSCLCs) and its relationship with immune cells. Immunohistochemical 
      staining to CTAs such as MAGE-A3/6 and NY-ESO-1 was performed using paraffin 
      blocks from 132 cases of NSCLCs, including 75 cases of squamous cell carcinoma 
      (SqCC) and 57 cases of adenocarcinoma (AdC), and the results were evaluated to 
      correlate with tumor-infiltrating DCs and CTLs and clinicopathologic features. 
      MAGE-A3/6 and NY-ESO-1 were expressed in 50.0% (66/132) and 18.2% (24/132) of 
      NSCLCs, respectively. MAGE-A3/6 was expressed more frequently in SqCC than in 
      AdC, but the expression of NY-ESO-1 showed no difference in both types. CTAs 
      revealed a higher expression in male than in female. In advanced stage III, 
      NY-ESO-1-positive patients showed poorer survival than NY-ESO-1-negative 
      patients. Otherwise, the CTA expression did not correlate with clinicopathologic 
      parameters. No relationship was found between DC and CTL infiltration in all 
      NSCLCs. Regarding DC infiltration, the group showing negative expression to CTAs 
      displayed an even higher number of infiltrating DCs than those showing positivity 
      to one or the other or both CTAs. Although the aberrant expression of MAGE-A3/6 
      and NY-ESO-1 in NSCLC did not directly influence clinical prognostic factors, the 
      higher expression of MAGE-A3/6 in SqCC suggests its value as a potential target 
      for immunotherapy in this type of NSCLC. The inverse relationship between DCs and 
      CTA expression may indicate that CTA-positive tumor cells would be akin to tumor 
      stem cells escaping host immune response.
FAU - Kim, Sang Hyun
AU  - Kim SH
AD  - Department of Pathology and Medical Research Institute, Pusan National University 
      School of Medicine, Beomeo-ri, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do, 
      626-770, Korea.
FAU - Lee, Sangyull
AU  - Lee S
FAU - Lee, Chang Hun
AU  - Lee CH
FAU - Lee, Min Ki
AU  - Lee MK
FAU - Kim, Young Dae
AU  - Kim YD
FAU - Shin, Dong Hoon
AU  - Shin DH
FAU - Choi, Kyung Un
AU  - Choi KU
FAU - Kim, Jee Yeon
AU  - Kim JY
FAU - Park, Do Youn
AU  - Park DY
FAU - Sol, Mee Young
AU  - Sol MY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091001
PL  - United States
TA  - Lung
JT  - Lung
JID - 7701875
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (CTAG1B protein, human)
RN  - 0 (MAGEA3 protein, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (Neoplasm Proteins)
SB  - IM
MH  - Adenocarcinoma/immunology/mortality/pathology
MH  - Adult
MH  - Antigens, Neoplasm/*immunology
MH  - Carcinoma, Non-Small-Cell Lung/*immunology/mortality/pathology
MH  - Carcinoma, Squamous Cell/immunology/mortality/pathology
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Humans
MH  - Korea
MH  - Lung Neoplasms/*immunology/mortality/pathology
MH  - Male
MH  - Membrane Proteins/*immunology
MH  - Middle Aged
MH  - Neoplasm Proteins/*immunology
MH  - Neoplasm Staging
MH  - Prognosis
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - *Tumor Escape
EDAT- 2009/10/02 06:00
MHDA- 2010/03/25 06:00
CRDT- 2009/10/02 06:00
PHST- 2009/07/07 00:00 [received]
PHST- 2009/09/10 00:00 [accepted]
PHST- 2009/10/02 06:00 [entrez]
PHST- 2009/10/02 06:00 [pubmed]
PHST- 2010/03/25 06:00 [medline]
AID - 10.1007/s00408-009-9181-3 [doi]
PST - ppublish
SO  - Lung. 2009 Nov-Dec;187(6):401-11. doi: 10.1007/s00408-009-9181-3. Epub 2009 Oct 
      1.